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SUMMARY 
 
 Skin cancer is the most common cancer worldwide. Its incidence is doubling 
every 15-20 years likely because of an aging population, changes in behaviour towards 
sun exposure, and increased UV light fluency at the earth surface due to ozone 
depletion. In this review, we summarize the most important genetic changes 
contributing to the development of malignant melanoma, basal cell carcinoma and 
squamous cell carcinoma, the main tumor entities arising in the skin. While our 
understanding of the oncogenes and tumor suppressor genes involved in the 
development and progression of skin tumors is still fragmentary, recent advances have 
shown alterations affecting conserved signalling pathways that control cellular 
proliferation and viability. These pathways include INK4a/Rb, ARF/p53, RAS/MAPKs, 
and sonic hedgehog/Gli.  
 
INTRODUCTION 
 
Skin is a complex tissue derived from both embryonic mesoderm and ectoderm 
that provides a barrier between the host and the environment. The epidermis, the outer 
layer of skin, is a multilayered squamous epithelium mostly formed by keratinocytes 
which is maintained through adult life by stem cells. Stem cells divide asymmetrically 
giving rise to one cell that remains as a stem cell (self-renewal) and another daughter 
cell that rapidly divides giving rise to a compartment of proliferating cells (transit 
amplifying cells). After a few cell divisions, all these cells undergo terminal 
differentiation and are shed constantly as dead keratinized squames (Fig. 1A). In 
addition to the keratinocyte, there are other three types of specialized cells in the 
epidermis: the melanin pigment- producing melanocyte,; the Langerhans cell that acts as 
an antigen-presenting cell in the lymph nodes; and the Merkel cell which is considered 
as an adapting mechanoreceptor (Fig. 1A). Besides preventing insensible loss of body 
fluids, the epidermis has the role to protect the body of environmental attacks, such as 
ultraviolet (UV) radiation, chemicals, viruses and other pathogens. As a result, 
epidermal cells have a high risk in acquiring gene mutations that could lead to the 
development of cancer. In particular, UV light exposure is the main responsible for the 
three major forms of human skin cancer: malignant melanoma, basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC). A fourth member of skin tumors that will 
be not included in this review is the rare but highly aggressive Merkel cell carcinoma1.  
UV light is divided into UVB (290-320 nm) and UVA (320-400 nm). UVC (< 
290 nm) is completely absorbed by the atmosphere and is non-relevant for UV-induced 
skin carcinogenesis. Most of UVB light is also absorbed by ozone, but 5-10% of it 
reaches the earth surface. Notably, the exposure to the high penetrating UVB radiation 
leads to DNA lesions, such as the formation of cyclobutane pyrimidine dimer and 
pyrimidine pyridine photoproducts. The incorrect repair of these products produces 
DNA mutations (C to T and CC to TT transitions). UVA genotoxicity seems to be 
induced by indirect mechanisms mediated by reactive oxygen radicals2. In the skin, 
melanin is the pigment synthesized within specialized cytoplasmic organelles 
(melanosomes) in melanocytes. Melanin acts as a filter by absorbing solar radiation. 
Melanosomes are transferred to neighbouring keratinocytes within the epidermis, and 
the number, location and melanin content of the melanosomes within the keratinocytes 
determine skin and hair colour (see below and Fig. 1B). 
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INHERITED CUTANEOUS CANCER SYNDROMES 
 
 Inherited cancer syndromes have contributed significantly to the understanding 
of the genetic lesions involved in the genesis of both familial and sporadic forms of the 
disease. Two forms of inherited cancer syndromes are specific for skin tumors: familial 
melanoma and the nevoid basal cell carcinoma syndrome or Gorlin syndrome. In 
addition, a clear predisposition to develop all three forms of skin cancer is found in 
patients suffering xeroderma pigmentosum. 
 
Familial melanoma 
 
 Familial melanomas represent about 8-12% of all melanoma cases. Linkage 
analysis studies of families with high melanoma incidence led to the identification of a 
locus at 9p21 in which the first melanoma susceptibility gene, CDKN2A, was identified. 
CDKN2A encodes two unrelated proteins: p16INK4a and p14ARF (p19 in mice) that 
are potent tumor suppressors involved in cell cycle regulation (Fig. 2A). p16INK4a 
specifically inhibits CDK4/CDK6-mediated phosphorylation of the retinoblastoma (Rb) 
protein arresting cell cycle progression through G1-S. p14ARF, on the other hand, 
enhances apoptosis and blocks oncogenic transformation by stabilizing p53 levels. 
Overall, germline CDKN2A mutations have been found in 20-40% of familiar 
melanomas. They comprise missense mutations found in exons 1 and exon 2, as well 
as in the 5’ untranslated region and introns3. As p16INK4a shares exon 2 with p14ARF 
(see Fig. 2A) many CDKN2A mutations affect both proteins confounding the specific 
role of each gene in melanoma genesis. However, mutations affecting only p14ARF 
have been described in some melanoma families4, thus pointing to ARF as a melanoma 
susceptibility gene that is independent of INK4a. In fact, genetically mouse models have 
provided convincing evidence that both ARF and INK4a are tumor suppressor genes in 
melanoma development5. In addition, genetic studies in melanoma families point to an 
additional unknown locus proximal to CDKN2A in the same chromosomal region as a 
risk gene for melanoma formation4. Other studies led to the finding of CDK4 (located at 
12q14) as a second melanoma susceptibility gene. Germline and sporadic mutations in 
CDK4 abrogating binding of p16INK4a to CDK4 (Fig. 2A) have been found associated 
with melanoma pathogenesis. Thus, mutations of this gene have a similar impact to 
those in p16INK4a, and phenotypic characteristics of the families carrying CDK4 
germline mutations do not differ from CDKN2A affected families6. Consistent with the 
human data, mice expressing a mutant form of cdk4 are predisposed to develop 
melanoma after carcinogen treatment7.  
  It is well known that melanomas are most common in fair-skinned individuals 
with red or blond hair and freckling phenotype. Since certain melanocortin-1 receptor 
(MC1R) polymorphic variants are associated with these characteristics, this pigment 
regulating gene is seen as a risk modifier of melanoma. Moreover, MC1R variants 
increase melanoma penetrance in individuals harbouring CDKN2A germline mutations. 
The MC1R receptor is an important determinant for which type of melanin is produced 
by the melanocytes. Activation of MC1R by -melanocyte-stimulating hormone 
(MSH) leads to the expression of crucial pigmentary enzymes involved in melanin 
synthesis, such as tyrosinase, tyrosinase-related protein-1 (TRP-1) and dopachrome 
tautomerase (DCT) (see Fig. 1B). Most red hair phenotypes (and individuals who do not 
tan irrespective of the hair colour) have deficient MC1R function and are not able to 
synthesize the photoreactive eumelanin (black-brown pigment), but instead have more 
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of the photosensitizing and potentially mutagenic pheomelanin (reddish-yellow 
pigment)4. 
 
Nevoid basal cell carcinoma (Gorlin) syndrome 
 
 Our knowledge of the molecular biology of BCCs has come from the analysis of 
the nevoid basal cell carcinoma (NBCC) syndrome, also known as Gorlin syndrome. 
NBCC syndrome is an autosomal dominant disorder characterized by a wide range of 
developmental anomalies (i.e., neural and skeletal abnormalities) and predisposition to 
various cancers. These include medulloblastomas, meningiomas, rhabdomiosarcomas, 
ovarian and cardiac fibromas, fibrosarcomas, and significantly the development of 
multiple BCCs in the skin8,9. Obviously, the gene involved in this disease had to have a 
crucial role in both normal development and regulation of cell growth. This gene, 
mapped at 9q22-9q31, was identified as PTCH1 due to its significant homology to 
patched, already known to play a key role in Drosophila embryogenesis as part of the 
hedgehog signalling pathway. Hedgehog signalling also plays a vital role in regulating 
patterning, proliferation, survival and growth in vertebrate embryos and adults9. 
Patched1 (ptch1), the protein encoded by PTCH1 is a receptor of the secreted signalling 
glycoprotein sonic hedgehog (Shh, see Fig. 3). A PTCH1 homologue, PTCH2, located 
at 1p32-1p34, was later identified but its function remains unclear. Germline loss-of 
function mutations of PTCH1 leading to constitutive activation of the Shh signalling 
pathway have been found in patients with NBCC syndrome as well as in a substantial 
proportion of sporadic BCCs (Table 1). The majority of germline PTCH1 mutations in 
NBCC patients are rearrangements resulting in truncated proteins. As NBCC patients 
normally inherit a mutated copy of the PTCH1 gene, tumors are likely to arise after 
inactivation of the remaining allele. 
 
Xeroderma pigmentosum 
 
A predisposition to skin cancer is also associated with the rare hereditary 
syndrome xeroderma pigmentosum (XP). Individuals with XP carry a nucleotide 
excision DNA repair defect associated with an acute photosensitivity. The most 
significant characteristic of XP patients is a predisposition to develop multiple skin 
cancers, mostly SCCs but also BCCs and malignant melanomas. These tumors arise 
early in age on sun-exposed skin areas, and present higher levels of UV-specific 
mutations in key regulatory genes than the same tumors from individuals with normal 
nucleotide excision repair mechanisms10,11. A proportion of severely affected XP 
patients also exhibit neurological disorders and higher frequencies of brain tumors. 
 
MALIGNANT MELANOMA 
 
 It is believed that melanoma, the most aggressive skin tumor, results from 
intense intermittent UV light exposure, along with severe sunburn during childhood2,12. 
In contrast to BCCs, malignant melanomas (and also SCCs, see below) seem to develop 
as a multi-step process. Melanomas are histologically classified into five distinct stages: 
common acquired and congenital nevi without dysplasia, dysplastic nevi, radial-growth 
phase (RGP) melanoma, vertical-growth phase (VGP) melanoma and metastatic 
melanoma (Fig. 4A). RGP melanoma grow laterally and remains largely confined to the 
epidermis, while VGP melanoma invades the upper layers of the epidermis and 
penetrates into the underlying dermis and subcutaneous tissue forming expansile 
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nodules of malignant cells. It is believed that the crucial step in the evolution to 
malignant melanoma is the transition from RGP to VGP melanoma4.  
Despite its important role in melanoma predisposition, mutations in CDKN2A 
are rarely found in sporadic primary melanomas. In contrast, CDKN2A mutations are 
found frequently in melanoma cell lines. This discrepancy could reflect a selective event 
imposed by cell culturing due to the critical role of p16INK4a in senescence, as cells 
that lose p16INK4a escape senescence and become immortalized3. Activating mutations 
in protooncogenes leading to constitutive activation of the mitogen-activated protein 
kinase (MAPK) signalling cascade have been found in melanocytic lesions. Strikingly, 
mutations in BRAF resulting in constitutive activation of this serine/threonine kinase 
have been found in about 60% of melanoma samples and cell lines. RAF proteins are 
the primary mediators of RAS signalling, which links extracellular mitogenic stimuli to 
transcription of growth related genes via the MAPK pathway (Fig. 2B). Most of these 
BRAF mutations occur at a single site leading to the substitution of valine by glutamic 
acid (V600E) in the kinase domain3.  BRAF mutations are common in benign and 
dysplastic nevi pointing to a potential initiating role of BRAF in melanocyte 
transformation4. There have been also reports documenting mutations in RAS genes in 
melanocytic tumors. The most frequently mutated member of the family is NRAS, while 
mutations in HRAS and KRAS have only been found occasionally3. Activating point 
mutations in NRAS have been reported in as many as 56% of congenital nevi, 33% of 
primary melanomas and 26% of metastatic melanoma samples, but are rarely found in 
dysplastic nevi. This fact indicates the possible existence of two distinct evolutionary 
paths to melanoma progression, from benign and dysplastic nevi4 (Fig. 4A). 
Interestingly, NRAS and BRAF activating mutations are mutually exclusive, indicating 
that these genes function in the same cellular growth regulatory pathway. 
 Other studies support aberrant hepatocyte growth factor/scatter factor (HGF/SF) 
signalling associated with melanoma progression. Increased expression of c-MET, the 
tyrosine kinase receptor of HGF/SF, has been observed in metastatic melanoma. In 
addition, gain of the 7q33-qter locus (where c-MET is located) has been correlated with 
late stages of melanoma development4. Besides to stimulate proliferation and motility of 
cultured melanocytes, HGF/SF disrupts adhesion between melanocytes and 
keratinocytes by downregulating the expression of the cell-cell adhesion proteins E-
cadherin and desmoglein-1, which could favours deregulated cell proliferation and 
invasiveness. 
 PTEN encodes a lipid and protein phosphatase involved in negative regulation of 
the phosphatidylinositol 3-kinase (PI3K)-AKT signalling pathway. PTEN is among the 
tumor suppressor genes most frequently mutated in cancer. Involvement of PTEN in 
melanoma was suspected because LOH of 10q (where PTEN is located) occurs in 30-
50% of melanomas. Loss of PTEN leads to activation of the PI3K-AKT pathway that 
transmits potent cell proliferation and survival signals. The region deleted at 10q is, 
however, large and could include other tumor suppressor genes3. Several authors have 
reported that the overall mutation frequency of PTEN in primary melanomas and 
metastases is 5-15%3,4. The frequency of PTEN mutations increases up to 30-40% in 
melanoma cell lines, paralleling the difference observed for CDKN2A between tumors 
and cultured cells.  
Interestingly, the proportion of primary melanomas containing mutations in the 
gene encoding p53 (TP53) is consistently low (<5%). Although UV light-related TP53 
mutations are frequently observed in BCCs and SCCs (see below), the above 
observation suggests that UV-induced mutational inactivation of p53 is not involved in 
melanoma formation. 
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Recent studies with high resolution of array comparative genomic hybridization 
(CGH) platforms have revealed that the evolution of melanoma is shaped by extensive 
chromosomal rearrangements, particularly recurrent chromosomal gains/amplifications 
and losses/deletions, and that distinct genomic signatures correlate with melanomas 
arising in different anatomical sites with different UV exposure patterns13. These 
studies, in conjunction with gene-specific mutational analyses will provide more 
accurate classification schemes and help to design rational therapeutic approaches. 
 
BASAL CELL CARCINOMA 
 
 BCC is the most frequent skin tumor and the most common form of human 
cancer. As in melanoma, intense intermittent exposure to the sun during childhood and 
adolescence is associated with a higher risk for developing BCCs. Besides UV light, 
other risk factors, such as ionizing radiation, arsenic, psoralens and immunosuppression 
in organ transplant patients, have also been linked to the development of BCC14. BCCs 
rarely metastasize (< 0.1%) and are characterized by lack of chromosomal instability15,  
making them unusual carcinomas. Nevertheless, BCCs can be highly invasive locally 
and can cause massive tissue damage. It is now generally accepted that BCCs are hair 
follicle-derived tumors and that they result from inappropriate activation of the Shh-Gli 
signalling pathway (Fig. 3) in hair follicle keratinocytes. Thus, overexpression of Gli1, 
Gli2 and Ptch1 (all of them targets of Shh signalling, see the legend of Fig. 3) has been 
consistently found in BCCs10.  
Mutations in PTCH1 (either rearrangements resulting in a truncated protein or 
point mutations leading to premature protein termination) are relatively frequent in 
sporadic BCCs10. In contrast, mutations in SHH are extremely rare in these tumors 
(Table 1). The mutational spectrum in the PTCH1 gene indicates a major role of UV 
light in the development of sporadic BCCs, as about 50% of these mutations are UVB-
specific C to T or CC to TT. Loss of the wild type allele has been demonstrated in up to 
68% of sporadic tumors, in accordance with a tumor suppressor mechanism for 
PTCH116.  Interestingly, mutations in the SMO gene have also been found in sporadic 
BCCs. The majority of SMO mutations are located in the extracellular domains of the 
Smo protein. These mutations may alter the latent state of Smo (by releasing Ptch1 
inhibition) and result in constitutive activation of Shh signalling. Therefore, SMO can 
be viewed as a protooncogene and, in fact, Smo mutants cooperate with other oncogenic 
proteins in transformation of rat embryo fibroblasts. In BCCs of XP patients the 
frequency of mutations in the different partners involved in the Shh pathway are 
substantially increased, particularly that of PTCH1 (Table 1). Genetically engineered 
mouse models for different partners of the Shh pathway strongly indicate that activation 
of Shh signalling is sufficient for BCC formation9,10. Thus, overexpression of Shh, Gli1 
or Gli2 in the skin of transgenic mice leads to BCC-like tumors. In addition, human 
keratinocytes overexpressing Shh also display abnormal BCC-like structures when 
grafted onto immune deficient mice. Interestingly, ptch1+/- knock-out heterozygous 
mice do not develop BCCs but only small follicular tumors. Nevertheless, ptch1+/- mice 
do develop BCC-like lesions after being exposed to UV or ionizing radiation17.  
 Mutations in the TP53 tumor suppressor gene have been found in approximately 
50% of sporadic BCCs. Although these mutations show the UVB signature its relevance 
for the development of BCC is not clear at present8,15. Several data suggest that p53 
mutations in BCCs are secondary events that do not contribute significantly to 
tumorigenesis, while other authors postulate that p53 mutations are crucial but a late 
event in tumor progression15. 
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SQUAMOUS CELL CARCINOMA 
  
 In contrast to BCC, cutaneous SCC is an aggressive tumor that may metastasize 
(commonly at lymph nodes) at frequencies reported between 1% and 12.5%. It is 
believed that SCCs arise from basal keratinocytes of the interfollicular epidermis in 
chronically sun-exposed skin, as these tumors are characterized by squamous 
differentiation. Whereas early-age recreational and intermittent intense sun exposure has 
been linked to BCC and malignant melanoma, high cumulative lifetime sun exposure 
has been associated with a higher risk for developing SCC18,19. The incidence of SCC is 
also high in patients receiving immunosuppressive therapy, a process that may be 
enhanced by concomitant human papilloma virus (HPV) infection. In individuals with 
intact immune system, however, there is no clear evidence for a role of HPV in the 
pathogenesis of this tumor. SCC develops as a classical cancer through well defined 
histological precancerous stages. Actinic keratoses (AK), a focal dysplasia of epidermal 
keratinocytes, and SCC in situ (CIS, also known as Bowen disease), a severe dysplasia, 
are preinvasive stages of invasive SCCs (Fig. 4B). Another skin lesion which is 
controversially discussed in this sequence of tumor evolution is the keratoacanthoma, a 
benign squamous neoplasm characterized by a rapid growth phase and then spontaneous 
regression after several months20.  
 The TP53 locus appears to play a significant role in the pathogenesis of SCC. 
p53 is involved in the induction of epidermal cell apoptosis following UV radiation-
mediated DNA damage21. Therefore, the loss of p53 provides a survival advantage to 
UV-damaged keratinocytes. TP53 is mutated in 60-90% of SCCs and AKs, and the 
mutations often display a typical UVB signature (C to T or CC to TT). TP53 point 
mutations appear to arise early and are often found in cases with mild or moderate 
dysplasia. LOH affecting the TP53 locus (which is located at 17p13.1) is more common 
at later stages, likely associated with the transition from AK to CIS19. In addition, a 
number of other chromosomes have been shown to carry LOH in SCCs, mostly 
restricted to 3p, 9p, 9q, 13q, 17p and 17q20. Despite the important role played by p53 in 
the development and progression of sporadic SCCs, it is interesting to note that 
individuals suffering the Li-Fraumeni syndrome due to a germline inherited mutation in 
TP53 do not appear to be at increased risk for SCC22. In contrast, these patients are 
prone to develop a wide variety of internal neoplasms, including sarcomas, breast 
cancer, brain tumors, and lymphomas, in accordance with TP53 being the most 
important tumor suppressor gene in human cancer. Mutations at lower frequencies than 
that of TP53 have also been found in other cancer-related genes. Thus, UV-induced 
mutations in HRAS and KRAS have been characterized in both AKs and SCCs22.  
Progression from AK to SCC has been suggested to correlate with deletion of 
CDKN2A, and immunohistochemical analysis demonstrating the presence of p16INK4a 
in AK but its absence in SCC supports these LOH studies19. However, a recent study 
has shown that promoter methylation might be the predominant mechanism for 
inactivation of both p16INK4a and p14ARF in sporadic SCCs23. It should be 
emphasized, in this regard, that concomitant inactivation of these two non-overlapping 
pathways, ARF/p53 and INK4A/Rb, must be cooperative in promoting tumorigenesis. 
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Legends to Figures 
 
Figure 1. (A) Schematic representation of the epidermis showing the main cell types 
forming this tissue. The epidermis is spatially organized in different cell layers. 
Keratinocyte proliferation takes place on the basal layer. Most spinous cells have lost 
the ability to divide but they are metabolically active. Granular cells occupy an 
intermediate position between spinous cells and metabolically inactive cornified cells 
(squames) of the stratum corneum. (B) Biochemical pathways leading to the synthesis 
of melanins. TRP-1, tyrosinase-related protein-1; DCT, dopachrome tautomerase (also 
called TRP-2). 
 
Figure 2. (A) CDKN2A locus. The CDKN2A gene encodes two proteins p16INK4a and 
p14ARF. Each has a unique first exon (1 or 1) that then splices to a common second 
and third exon, but in alternate reading frames. p16INK4a binds and inhibits the 
activities of the cyclin-dependent kinases CDK4 and CDK6 ensuring that Rb remains in 
a hypophosphorylated state in complex with E2F transcription factor, leading to G1 
arrest. p14ARF stabilizes and enhances p53 levels by inhibiting MDM2-mediated p53 
ubiquitylation and degradation through the proteasome. p53 accumulation leads to 
either cell cycle arrest or cellular apoptosis. (B) The RAS/MAPK signalling pathway. 
After binding of growth factors to their respective receptor tyrosine kinase (RTK), 
activation of RTKs leads to binding of SOS (a cytosolic protein in close proximity to 
RAS on the plasma membrane) to the GDP-bound inactive form of RAS. Like other G 
proteins, RAS cycles between the GDP-bound inactive form and the GTP-bound active 
form. The binding of SOS to RAS induces a conformational change that leads to the 
dissociation of GDP and binding of GTP. The best characterized RAS effector pathway 
proceeds via a kinase cascade that involves phosphorylation of RAF. RAF in turn 
phosphorylates MEK which then phosphorylates ERK MAPKs. Activated ERKs 
translocate into the nucleus where they phosphorylate specific transcription factors that 
are involved in the regulation of various cellular responses, particularly in promoting 
cell proliferation.  
 
Figure 3. The sonic hedgehog signalling pathway. When Shh is absent, the 12-pass 
transmembrane receptor protein ptch1 inhibits smoothened (Smo), a 7-pass G-protein-
coupled-like receptor that acts as a transducer of the Shh signal. Smo is released upon 
binding of Shh to Ptch1 initiating a signal transduction cascade that results in activation 
of the multifunctional zinc finger transcription factors Gli. Gli proteins are sequestered 
in the cytoskeleton forming a complex with Fused and Sufu (suppressor of Fused). 
Activation of the pathway leads to dissociation of Gli from this complex and 
translocation into the nucleus. There are three human Gli proteins: Gli1, Gli2 and Gli3. 
Genes regulated by Shh include the Wnt family of growth factors, the bone 
morphogenetic proteins (BMPs) members of the TGF- superfamily, the platelet-
derived growth factor receptor PDGFR, the winged helix domain transcription factor 
FOXE1 (which is specifically expressed in epidermal basal keratinocytes), as well as 
components of the Shh pathway itself, such as Ptch1, Ptch2 Gli1, and Gli29,10. 
 
Figure 4. Genetic alterations involved in the development of malignant melanoma (A) 
and squamous cell carcinoma (B). Both cancers are thought to arise by a multi-step 
process. For additional details see the text. RGP, radial growth phase; VGP, vertical 
growth phase; AK, actinic keratoses; CIS, carcinoma in situ; SCC, squamous cell 
carcinoma. 
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Table 1. Frequency of mutations in components of the Shh pathway found in hereditary 
and sporadic BCCs*  
------------------------------------------------------------------------------------------------------ 
   SHH   PTCH1  SMO  
------------------------------------------------------------------------------------------------------ 
NBCC syndrome    -      Germline mutations          - 
                and LOH 
 
XP BCCs  18%   73-88%  30% 
 
Sporadic BCCs ~1%   12-38%  6-13% 
------------------------------------------------------------------------------------------------------ 
* Adapted from ref. 10   
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